ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid cddo-me in ovarian cancer cells

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 215-222

  Gao, Xiaohua ^a   Liu, Yongbo ^a   Deeb, Dorrah ^a   Liu, Patricia ^a   Liu, Annie ^a   Arbab, Ali S ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

AKT; Apoptosis; CDDO Me; MTOR; NF B; Ovarian cancer; ROS

Indexed keywords

ACETYLCYSTEINE; BARDOXOLONE METHYL; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SURVIVIN; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

ACETYLCYSTEINE; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYDROGEN PEROXIDE; OLEANOLIC ACID; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84873028936     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. American Cancer Society. Cancer Facts and Figures 2010. Atlanta, Ga. Accessed April 14, 2011.
2. Berek JS: Ovarian Cancer. In: Practical Gynecologic Oncology 4th edition. Berek JS and Hacker NF (eds.): Philadelphia, PA: Lippincott Williams & Wilkins pp, 443-451, 2005.
3. Du Bois A, Neijt JP and Thigpen JT: First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-A new standard of care? Ann Oncol 10(Suppl 1): 35-41, 1999.
4. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B and van Houwelingen HC: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092, 2000.
5. Nishino H, Nishino A, Takayasu J, Hasegawa T, Iwashima A, Hirabayashi K, Iwata S and Shibata S: Inhibition of the tumorpromoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res 48: 5210-5215, 1988.
6. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, and Gautam SC: Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival AKT, NF-kappaB and Notch1 signaling. J Neurooncol 84: 147-157, 2007.
7. Deeb D, Gao X, Jiang H, Janic B, Arbab AS, Rojanasakul Y, Dulchavsky SA and Gautam SC: Oleanane triterpenoid CDDOMe inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol 79: 350-360, 2010.
8. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB and Andreeff M: The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspasedependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64: 7927-7935, 2004.
9. Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H and Seiden MV: CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and STAT3 phosphorylation in multidrug-resistant ovarian cancer cells. Cancer Chemother Pharmacol 63: 681-689, 2009.
10. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M and Ruvolo PP: The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19: 1350-1354, 2005.
11. Yore MM, Liby KT, Honda T, Gribble GW and Sporn MB: The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 5: 3232-3239, 2006.
12. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A and Sporn MB: The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and NRF2/ARE signaling. Cancer Res 65: 4789-4798, 2005.
13. Gao X, Liu Y, Deeb D, Arbab AS, Guo AM, Dulchavsky SA and Gautam SC: Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-kappaB/mTOR signaling. Anticancer Res 31: 3673-3681, 2011.
14. Nohl H, Kozlov AV, Gille L and Staniek K: Cell respiration and formation of reactive oxygen species: Facts and artefacts. Biochem Soc Trans 31: 1308-1311, 2003.
15. Martindale JL and Holbrook NJ: Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192: 1-15, 2002.
16. Sun Y and Rigas B: The thioredoxin system mediates redoxinduced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 68: 8269-8277, 2008.
17. Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, Evans R, Contractor R and Andreeff M: A novel mechanism of action of methyl-2-cyano-3, 12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol 69: 1182-1193, 2006.
18. Burdon RH: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 18: 775-794, 1995.
19. Torres M and Forman HJ: Redox signaling and the MAP kinase pathways. Biofactors 17: 287-296, 2003.
20. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: AKT phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
21. Mayo MW and Baldwin AS: The transcription factor NFkappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470: M55-62, 2000.
22. Bjornsti MA and Houghton PJ: The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4: 335-348, 2004.
23. Lee SJ, Seo KW, Yun MR, Bae SS, Lee WS, Hong KW and Kim CD: 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the AKT/NF-kappaB signaling pathways. Free Radic Biol Med 45: 1487-1492, 2008.